Skip to main content
Cell Stress logoLink to Cell Stress
. 2019 May 27;3(6):181–194. doi: 10.15698/cst2019.06.189

Remodeling of mitochondrial morphology and function: an emerging hallmark of cellular reprogramming

Anuj Rastogi 1, Piyush Joshi 2,3, Ela Contreras 1, Vivian Gama 1,2,3,4,*
PMCID: PMC6558935  PMID: 31225513

Abstract

Research in the stem cell field has traditionally focused on understanding key transcriptional factors that provide pluripotent cell identity. However, much less is known about other critical non-transcriptional signaling networks that govern stem cell identity. Although we continue to gain critical insights into the mechanisms underlying mitochondrial morphology and function during cellular reprogramming – the process of reverting the fate of a differentiated cell into a stem cell, many uncertainties remain. Recent studies suggest an emerging landscape in which mitochondrial morphology and function have an active role in maintaining and regulating changes in cell identity. In this review, we will focus on these emerging concepts as crucial modulators of cellular reprogramming. Recognition of the widespread applicability of these concepts will increase our understanding of the mitochondrial mechanisms involved in cell identity, cell fate and disease.

Keywords: BCL-2 family, mitochondria, mitochondrial dynamics, apoptosis

INTRODUCTION

A paradigm shift from considering mitochondria mere powerhouses of the cell to realizing that they are a major regulatory hub began two decades ago with two discoveries: (1) that cytochrome c, a protein known previously only as an electron transporter, triggers cell disassembly during apoptosis once released into the cytoplasm [1]; and (2) that the B-Cell Lymphoma-2 (BCL-2) family controls this release [2]. Another shift followed from discovering that mitochondria are highly dynamic organelles, which fuse into each other and divide rapidly and reversibly in response to internal and external environmental cues. Subsequent discoveries established that mitochondrial fusion and fission (division), which are collectively known as mitochondrial dynamics [3, 4], are involved in aging [5], neurodegenerative diseases [6], and tumorigenesis [79]. Recent studies provide compelling evidence for a novel function of mitochondrial dynamics in human pluripotent stem cells (hPSCs). These investigations have revealed that the BCL-2 family is essential in hPSCs not only during cell death, but also through its ability to regulate the mitochondrial network, which is key for other cell fate decisions, such as self-renewal and pluripotency [1012].

Stem cells can be divided into three main types: embryonic stem cells (ESCs), adult stem cells, and induced pluripotent stem cells (iPSCs). ESCs and iPSCs are defined by two key properties: self-renewal (defined as the ability to proliferate without lineage commitment) and pluripotency (defined as the ability to differentiate into the three main tissue lineages). Since the first human ESC (hESC) line was derived in 1998, hESCs have become efficient tools to study processes of human development and various aspects of human diseases, like cancer [13]. Since cells from the inner cell mass, from which ESCs are derived, can give rise to all tissues derived from germ layers (endoderm, mesoderm, and ectoderm), genomic instability is especially risky for their self-renewal and organ specific differentiation. Thus, not surprisingly, these cells are endowed with exquisite mechanisms to respond rapidly to apoptosis-inducing stress. Various studies have provided evidence of changes in apoptosis regulation, mitochondrial dynamics and metabolic function and regulation during the process of reprogramming (i.e. reverting a differentiated cell into a stem-like state, through the expression of master pluripotency transcription factors such as, OCT4 (Octamer-binding transcription factor 4), SOX2 (SRY(sex-determining region Y)-box 2), KLF4 (Kruppel-like factor 4) and c-MYC, collectively known as OSKM) [14, 15].

Mitochondria-related hallmarks of reprogramming are beginning to emerge. In this review, we specifically discuss three biological capabilities acquired during the multistep transition of a somatic cell into a pluripotent stem cell. They include: inherent sensitivity to apoptosis, changes in mitochondrial morphology and localization, and a modified functional state of the mitochondria (i.e changes in metabolic requirements) [10, 11, 1317] (Figure 1). In the following sections, we will explore the known underlying mechanisms involved in these changes highlighting recent discoveries as well as describe areas that are open to more detailed investigation. While we propose that these three mitochondria-related hallmarks constitute a requirement for reverting a differentiated cell into a stem cell, there are other mitochondrial events such as mitochondrial biogenesis, mitochondrial trafficking and mitochondrial transcription that also undergo dramatic changes during cellular reprogramming and that could also be essential for successfully reverting cell fate. Additional studies are needed to elucidate the impact of these events on the reprogramming process.

Figure 1. FIGURE 1: Emerging mitochondria-related hallmarks of reprogramming.

Figure 1

Left side: Differentiated cells (such as fibroblasts) have an elongated mitochondrial network with a preference for oxidative phosphorylation (OXPHOS) as a source of energy and are relatively resistant to apoptosis stimuli. Right side: After reprogramming, cells now have a fragmented mitochondrial network with a switch to using glycolysis as a preferred bioenergetic source. Cells become increasingly sensitive to cell death due to at least two main mechanisms: increased mitochondrial priming and pre-activated BAX.

INCREASED SENSITIVITY TO CELL DEATH

The apoptotic process involves morphologic changes including cell constriction, chromatin condensation, nuclear envelope disruption followed by nucleus breakdown to discrete bodies, plasma membrane blebs formation, and finally the break-up of the cell into apoptotic bodies [18]. Activated cysteine proteases known as caspases cleave many vital cellular proteins (nuclear scaffold, cytoskeleton, etc.) followed by nuclear DNA degradation [19, 20]. Caspase dependent apoptosis is classified into extrinsic and intrinsic pathways, mediated by death ligands and mitochondria respectively [21]. Our focus in this review will be on the mitochondrial pathway of apoptosis (Figure 2). The extrinsic pathway of apoptosis has been described extensively in several excellent reviews [2224].

Figure 2. FIGURE 2: Scheme of the mitochondrial pathway of apoptosis.

Figure 2

Stress-induced activation of BAX/BAK leading to mitochondrial outer membrane permeabilization and cytochrome c release to the cytosol. Anti-apoptotic proteins block BAK/BAX activation/oligomerization induced by BH3-only proteins. BCL-XL: B-cell lymphoma extra-large; MCL-1: myeloid cell leukemia 1; BID: BH3-interacting domain death agonist; BIM: BCL-2 interacting mediator of cell death; PUMA: P53-upregulated modulator of apoptosis.

The intrinsic apoptosis pathway, also known as the mitochondria mediated cell death pathway, is a form of regulated cell death initiated by a variety of perturbations including DNA damage [24]. These stresses induce the activation of the transcription factor P53 that then initiates a response to arrest cell cycle and repair DNA [25, 26]. If repair is not achieved, an apoptosis response is triggered leading to the activation of the BCL-2 associated X (BAX) and/or BCL-2 antagonist killer 1 (BAK1; best known as BAK), these pro-apoptotic effector proteins of the BCL-2 family then permeabilize the outer mitochondrial membrane [2733. BAX and BAK can be directly activated via binding to a subset of BH3-only proteins known as “activators” (i.e. BCL-2 interacting mediator of cell death (BIM), BCL-2 interacting domain death agonist (BID), P53-upregulated modulator of apoptosis (PUMA), and phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1, best known as Noxa) [32, 33]. The anti-apoptotic members of the BCL-2 family (e.g. BCL-2, apoptosis regulator (BCL-2), BCL2-like 1 (best known as BCL-XL) and Myeloid Leukemia Sequence 1 (MCL-1)) can also bind to BAX and prevent its function. BH3-only proteins known as “sensitizers” (e.g. BCL2 associated agonist of cell death (BAD), and BCL-2 modifying factor (BMF)) inactivate the anti-apoptotic BCL-2 family proteins, and therefore may also be needed for efficient BAX and BAK activation [24, 3234]. Early studies examining the interaction between BH3-only proteins and the anti-apoptotic proteins revealed differential binding patterns that have been exploited to examine the apoptotic vulnerability of various cells of interest [3538]. Mitochondrial outer permeabilization induced by BAX and BAK, then results in the release of cytochrome c, oligomerization of the Apoptotic Protease Activating Factor-1 (APAF-1) and the activation of the executioners of apoptosis, a family of cysteine proteases termed caspases [3941]. Caspases cleave intracellular targets [42], resulting in the morphological changes previously described, and cellular demise [24, 43].

In contrast to differentiated cells, BAX is kept in an active state in hESCs and sequestered at the Golgi network [14, 44] (Figure 3). Upon DNA damage, active BAX rapidly translocates from the Golgi to mitochondria, triggering apoptosis. Such a rapid response may be critical for preventing the propagation of aberrant cells in the developing embryo, or the emergence of a cancerous cell in the tissues of an adult organism, acting as sort of “cocked gun”. This “cocked gun” is disarmed once the cell differentiates [14, 44], implying that the cell uses specific mechanisms for inactivation, which are unknown. An additional study followed these observations and determined that mitochondrial priming also contributes to the increased apoptosis sensitivity of hESCs compared to differentiated cells [15]. The balance between pro and anti-apoptotic factors shifts more towards the apoptotic threshold in hESCs [15, 44]. How the high mitochondrial priming state is initiated and maintained in hPSCs, as well as how it is reset early during differentiation is not known. Considering the phenomenon of mitochondrial priming and the fact that BAX is constitutively activated in hPSCs, we hypothesized that proteins of the BCL-2 family have uncharacterized functions in hPSCs that are unrelated to cell death.

Figure 3. FIGURE 3: BAX activation in stem cells.

Figure 3

Besides high mitochondrial priming, human ESCs also have an active form of BAX at the Golgi that rapidly translocates to the mitochondria under apoptosis stimuli. Active form of BAX: BAX 6A7; Golgi apparatus marker: TGN46.

Interestingly, both caspases and P53 play a major part in the generation of iPSCs. However, the mechanistic details of their involvement in somatic cell reprogramming are unknown. Apoptosis serves a defensive role by eliminating genetically abnormal and damaged cells from the pluripotent population [4548]. Thus, antagonizing apoptosis by overexpression of anti-apoptotic BCL-2 or via repression of P53 significantly improves the efficiency of iPSC generation [49, 50]. Previous studies showed that Caspase-8 deficient animals die in their early developmental stages due to improper differentiation of neural precursors [51]. This correlation between caspases and the ability of embryonic stem cells to self-renew or differentiate was later demonstrated by the report that caspase-3 and caspase-9 mutant mouse ESCs (mESCs) are unable to differentiate [52]. A caspase-dependent degradation site in the stem cell factor NANOG is conserved between mice and human protein homologues, providing insight into the mechanism by which caspases regulate reprogramming efficiency [52]. Caspase-3 dependent degradation of NANOG was reported as a key factor leading to the differentiation of hESCs and iPSCs in the absence of basic fibroblast growth factor [53]. In contrast to their role in ESCs, activated caspase-3 and caspase-8 via degradation of Retinoblastoma protein (RB), help in the de-differentiation of human fibroblasts into iPSCs [54]. Thus, caspases play a dual role by driving dedifferentiation of somatic stem cells and differentiation of ESCs, in the context of cellular and substrate availability. The use of caspase inhibitors may work as a fine regulator for differentiating ESCs/iPSCs and for reprogramming iPSCs. Hence, further investigation of underlying molecular mechanisms of caspase regulation is needed.

Numerous studies have demonstrated that P53 is essential for embryonic development and cellular differentiation [55]. P53 transcriptional activity in cellular differentiation is context dependent having contradictory results in various cell types [55]. For instance, P53 enhances the differentiation of both murine and human ESCs in the presence of retinoic acid and DNA damage [56, 57] whereas, P53 is also shown to promote hematopoietic stem cell (HSC) quiescence and inhibit neural stem cell proliferation [58, 59]. Use of the MDM2 inhibitor nutlin-3a results in rapid accumulation of P53 and subsequent induction of apoptosis and rapid differentiation in hESCs, but it has a minimal effect in somatic cells [60, 61]. Similar to the observations that stabilization of P53 plays a role in differentiation of ESCs, various studies have shown that inactivation of P53 helps in reprogramming of somatic cells to iPSCs [49, 62, 63]. Considering that iPSCs and malignant somatic cells share similar characteristics (higher proliferation, transcriptional and metabolic status), the negative role of P53 in cellular reprogramming is not unexpected. Mechanistic insights for P53's inhibitory role in cellular reprogramming involves P53 mediated targeting of miR-34a that suppresses the expression of Sox2, MYC and NANOG [64], regulation of CDKN1A that attenuates cell division [48] and inhibition of specific epithelial genes that further suppress mesenchymal to epithelial transition [46].

Reprogramming efficiency of somatic cells to iPSCs is reduced in the absence of c-MYC. However, the tendency of MYC to cause apoptosis also represents a roadblock to reprogramming. A recent study indicates that reprogramming of mouse embryonic fibroblasts (MEFs) is enhanced in the absence of BAK and BAX under OKSM conditions [65]. These studies demonstrate that mitochondrial apoptosis imposes a strong MYC-dependent block to somatic cell reprogramming [10, 50, 65, 66]. Hence, although MYC expression favors reprogramming by regulating cellular processes (transcription, translation, ATP generation) [67, 68], its tendency to sensitize cells to mitochondrial apoptosis is an interesting paradox. Intriguingly, high γ-H2A.X deposition has been described in hPSCs and it has been linked to the global chromatin de-condensation required by pluripotent stem cells in order to dynamically activate transcriptional programs in response to environmental cues [69]. How these epigenetic changes are linked to increased mitochondrial apoptosis is not known. Understanding the exact mechanisms by which reprogramming induces epigenetic modifications, constitutive apoptosis sensitization and priming of pluripotent stem cells is an area in need of more investigations.

INCREASED MITOCHONDRIAL FISSION

Mitochondrial movement and fragmentation were first observed almost 100 years ago [70]. For decades these observations remained unexplored and the idea of mitochondria as isolated and static “jelly-bean” structures that serve as “power houses” of the cells became an unrefuted dogma. The development of new technologies made it easier to track mitochondria in live cells. These studies revealed the remarkable ability of mitochondria to move and to continually divide and fuse [7173]. Further studies have demonstrated that mitochondrial dynamics are crucial for normal physiology from yeast to mammals. Emerging studies demonstrate a connection between mitochondrial dynamics machinery, apoptosis and mitophagy. In addition, several human diseases result from mutations in fusion and fission proteins further highlighting the relevance of mitochondrial fission and fusion events in cellular homeostasis [8, 7477].

Interestingly, as differentiated cells transition to a stem cell state, the mitochondrial network undergoes dramatic changes. Mitochondria of stem cells contain functionally immature mitochondria with a globular shape, poorly developed cristae, and perinuclear localization, an indicator of a less active mitochondrial state [78, 79], whereas differentiated cells, like fibroblasts, have a complex morphology with well-developed cristae, dense matrix, and elongated appearance. It is not completely understood how increased mitochondrial fragmentation is maintained in stem cells, however, constitutive activation of the dynamin-related guanosine triphosphates (GTPases) is likely a contributing factor [79].

Dynamin-related GTPases control mitochondrial dynamics by allowing opposing processes of division and fusion to work in concert maintaining overall shape and number of mitochondria [76, 79]. Large dynamin-related GTPase proteins (DRPs) are highly conserved and have the ability to self-assemble and hydrolyze GTP to control mitochondrial fusion and fission [80, 81]. In mammals, fission or fragmentation of the mitochondrial network is mediated by dynamin related protein-1 (DRP-1). DRP-1 is primarily localized in the cytosol and recruited to mitochondria during fission. Activation of DRP-1 is mediated by post translational modifications including phosphorylation, sumoylation, O-GlcNAcylation and ubiquitination which are thought to enhance its recruitment to mitochondrial receptors [83]. The impact of these post-translational modifications for maintaining the homeostatic mitochondrial fragmentation in pluripotent stem cells is not known. Modified DRP-1 oligomerizes around mitochondria and constricts the network severing both mitochondrial inner and outer membranes. The structural domains and mechanistic details of action for DRP1 have been clearly elucidated [8, 8086]. DRP-1 is also involved in promoting mitochondrial fragmentation during apoptosis [87] (reviewed in next section).

Fusion of mitochondria requires Mitofusin 1 (MFN1), Mitofusin 2 (MFN2), and Optic Atrophy 1 (OPA1) to fuse the outer and inner mitochondrial membranes [8890]. Fusion is key for mitochondrial DNA (mtDNA) homogenization and assembly of electron transport chain. MFN1 and MFN2 are anchored in the outer mitochondrial membrane and allow for formation of homo- or hetero-dimers with MFNs facilitating fusion. The inner membrane is fused afterwards in a similar fashion by OPA1. OPA1 is localized to the inner mitochondrial membrane with GTPase domain exposed to inner membrane space. Overexpression of OPA1 leads to fragmentation of mitochondria, however, effects on cell death are not clear [91]. The mechanisms by which the activity of the dynamin-related proteins involved in fusion is regulated are not well understood, but data from in vitro assays illustrates that inner and outer mitochondrial fusion are separable and mechanistically different [92, 93]. Fission is necessary for cell division and for mitophagy when damaged mitochondria have to be segregated. As mentioned previously, mitochondrial dynamics are crucial for normal physiology from yeast to mammals [94]. Imbalance in the process of fusion and fission leads to severe pathophysiological conditions. These range from the inability to survive past mid-gestation in MFN1, MFN2, OPA1, or DRP-1 deficient mice [90, 90, 9597], to neurodegenerative diseases such as Charcot-Marie-Tooth syndrome and dominant optic atrophy [88, 89, 98, 99] caused by mutations in MFN2 and OPA1.

The BCL-2 family has recently been implicated as a key factor in maintaining stem cell self-renewal and pluripotency. Inhibition of pro-apoptotic BAX and BAK proteins has been reported to be required for mitochondrial fusion [80, 100102]. BAX has been suggested to regulate fusion by interacting with MFN1 and/or MFN2 [102, 103]. BCL-xL, an anti-apoptotic protein, has been shown to be highly expressed at the mitochondria of adult neurons and required for normal brain development [104]. BCL-xL appears to affect mitochondrial dynamics in mammalian neurons resulting in an increment of the length/size of mitochondria and the localization of mitochondria to synapses [105, 106]. Furthermore, the anti-apoptotic protein MCL-1 appears to be involved in the regulation of mitochondrial dynamics and the maintenance of pluripotency [10]. MCL-1 appears to interact with DRP-1 and OPA1 in hPSCs, and potentially other BCL-2 family members. This interaction may be critical for the modulation of mitochondrial dynamics (Figure 4). A recent study further demonstrates that the BH3-only protein BID also regulates mitochondrial morphology and cristae organization [12]. The functional implication of a potential MCL-1 and BID interaction in maintaining pluripotency and self-renewal ability of hPSCs has not yet been explored. Revealing the mechanistic link between the mitochondrial dynamics machinery and the BCL-2 family represents a unique opportunity for increasing our understanding of how these mitochondrial signaling pathways interact to regulate cell fate.

Figure 4. FIGURE 4: Mitochondrial dynamics.

Figure 4

Mitochondrial fusion and fission are regulated by guanosine triphosphatases (GTPases) proteins: DRP1 mediates fission, OPA1 and Mitofusins (not shown) regulate mitochondrial fusion. In stem cells, the anti-apoptotic protein MCL1 has been shown to interact with DRP1 at the outer mitochondrial membrane and with OPA1 at the matrix.

Mitochondrial remodeling during apoptosis

The mitochondrial pathway of apoptosis causes the remodeling of mitochondrial structure that ultimately enables the release of cytochrome c, the defining moment of apoptosis [87, 101, 107112]. Some studies suggest that BAX/BAK-mediated outer mitochondrial membrane permeabilization is not sufficient for cytochrome c release during apoptosis, but rather it requires mitochondrial fragmentation to occur first. Activation of BAX and BAK may lead to changes in mitochondrial cristae structure mediated by OPA1 monomerization which drives remodeling and opening of cristae junctions [113, 114]. It is clear that the fragmentation of the mitochondria during apoptosis is independent of caspase activity [115], and it takes place through two coordinated, but independent, events: opening of cristae junctions, where cytochrome c is bound, and formation of the outer membrane pores [87, 111, 116120].

DRP-1 colocalizes with the BAX/BAK pores [107, 121, 122] where it promotes disintegration of the mitochondrial network. The fragmented mitochondria collapse in a perinuclear pattern and show decreased and non-directed motility. Consistent with the increased mitochondrial fragmentation, mitochondrial fusion has also been shown to be blocked once apoptosis is activated [123].

Endoplasmic reticulum (ER) tubules frequently cross paths with mitochondria at points of impending fission and mark sites of mitochondrial division, a phenomenon known as ER-associated mitochondrial division (ERMD) [75, 124]. These studies also indicate that the ER might play an active role during the early stages of fission, even before DRP-1 severs the mitochondria. At these “hotspots” mitochondria are constricted and allow for assembly of the diversion DRP helix. The ER may be able to alter mitochondrial membrane composition, facilitate factors, such as MFF, on the inside and/or outside of mitochondria to promote fission; however, the mechanisms underlying ER-mitochondrial microdomain or ER-mitochondrial constriction is not well established [75]. While the function of DRP1 in constricting the mitochondria has been established using cancer cell lines, the exact mechanism by which DRP-1 regulates fragmentation during apoptosis or by which it maintains the constitutive fragmentation of the mitochondrial network in stem cells and some cancer stem cells is less clear. It will be interesting to determine if the DRP-1 mechanism of action and function in homeostatic conditions and stressed conditions is modified in stem cells and cancer stem cells where mitochondria are maintained in a more fragmented state.

While the high mitochondrial priming described in the first section and the increased mitochondrial fragmentation are two fundamental features that accompany entry into the pluripotent state, the protein network and exact signaling events that are modulating these changes remain elusive. We speculate that the BCL-2 family mediates both of these properties, and that reprogramming of differentiated cells into stem cells provides a useful tool to dissect this intriguing possibility. Examining the connection between mitochondrial priming, fragmentation and the acquisition of a particular stem cell fate opens an exciting opportunity for future studies to determine whether these properties are mechanistically related.

DECREASED MITOCHONDRIAL-DEPENDENT METABOLISM

The increased sensitivity to cell death as well as the structural and functional remodeling of the mitochondrial network described in previous sections are accompanied by an essential switch from oxidative phosphorylation (OXPHOS) to glycolysis during reprogramming. The detailed molecular mechanisms and the temporal regulation underlying this switch remains unclear. ESCs and iPSCs have a similar metabolic profile to many cancer cells that predominantly depend on glycolysis for rapid proliferation and self-renewal. There are landmark papers on the characterization of the differences in metabolic profiles between various stages of pluripotency in mPSCs (i.e., naïve PSCs, primed PSCs and epiblast stem cells) [125127]. In this section we will describe the main metabolic pathways involved in promoting cellular reprogramming and maintaining pluripotency in human PSCs [128].

Oxidative phosphorylation (OXPHOS)

OXPHOS is a primary source of ATP production in eukaryotic cells. A series of enzymes residing in the inner mitochondrial membrane oxidize the products of glycolysis and citric acid cycle to release protons into the inter-membrane space in the presence of oxygen. This establishes a proton gradient that drives the ATP synthase which shuttles back the hydrogen ions and produces 30 ATP molecules in the process, but it requires oxygen.

Energy production of PSCs rely heavily on glycolysis over OXPHOS [129131]. While OXPHOS results in increased production reactive oxygen species (ROS) that could be deleterious, low ROS levels produced at the mitochondria have been shown to be critical for signaling and cell survival [132]. Thus, maintaining functional respiratory complexes may be critical for generating endogenous levels of ROS critical for stem cell renewal and pluripotency. Mitochondrial uncoupling protein 2 (UCP2)-mediated suppression of OXPHOS is required for the maintenance of pluripotency. UCP2 decouples glycolysis from OXPHOS by shunting pyruvate out of the mitochondria [133]. However, it is not completely understood whether this suppression of OXPHOS in PSCs still results in permissive low levels of endogenous ROS. Redox levels and pathways involved in redox signaling have not been thoroughly studied during cellular reprogramming, and remain an open area of investigation.

Glycolysis

Glycolysis involves ten reactions in the cytosol that rapidly catabolizes each six-carbon glucose molecule to produce two ATP molecules, without the requirement of oxygen. Glycolysis generates pyruvate, which in most cell types, can be shunted into two metabolic fates: in the presence of oxygen, pyruvate enters the mitochondria where it is oxidized to acetyl-CoA via pyruvate dehydrogenase (PDH), whereas in the absence of oxygen, pyruvate is reduced into lactate via lactate dehydrogenase (LDH) [134138]. The intermediates in glycolysis can also be shunted into macromolecule synthesis during rapid cell growth. Thus, while it is a less efficient source of energy, glycolysis can generate both anabolic growth intermediates and ATP very rapidly owing to the much higher speed of glycolysis reactions. Primed pluripotent stem cells utilize glycolysis as a primary source of energy, converting glucose to lactate instead of directing the produced acetyl-CoA into the tricarboxylic acid cycle (TCA) cycle at the mitochondria as seen in mature differentiated cells which mostly rely on the TCA cycle for energy production [139141]. Glycolysis in PSCs is crucial for maintaining pluripotency. In fact, conversion to glycolysis is necessary for successful reprogramming as inhibition of glycolysis in hESCs has been shown to result in apoptosis and cell cycle arrest [142].

Interestingly, hypoxic conditions are known to stimulate glycolysis and have been shown to prevent the spontaneous differentiation of hESCs [143, 144]. As hypoxic niches are the primary residing locations for PSCs, glycolytic metabolism might represent an adaptation to their surroundings. The increased senescence in MSCs cultured under normoxia (21% O2) compared to when cultured under 5% O2 levels supports this hypothesis [145]. Hypoxia inducible factor-1 (HIF-1) regulates transcriptional activities and induces a switch from OXPHOS to glycolysis followed by suppression of mitochondrial biogenesis in response to hypoxia and thus, represent an important link between mitochondrial metabolism in PSCs and cellular reprogramming [146149].

Methionine metabolism

Human PSCs use high levels of methionine instead of threonine as seen in murine PSCs [126, 150]. This is because threonine dehydrogenase, which catabolizes threonine into 2-amino-3-ketobutyrate, evolved into a pseudogene in humans, unlike most other mammals [151]. Methionine provides the methyl group for many histone methyltransferases. Uptake of methionine from the culture media is required to maintain S-adenosylmethionine (SAM) levels in hPSCs. SAM is a methyl donor for histone methyltransferases (HMT) and DNA methyltransferases (DNMTs). Methionine deprivation results in a rapid decrease in SAM, loss of H3K4me3, and reduced NANOG expression which triggers human PSCs to differentiate. Prolonged methionine deprivation leads to cell cycle arrest and apoptosis in human PSCs [150]. SAM is consumed by NNMT (nicotinamide N-methyltransferase) which has been found upregulated in naïve hPSCs [152]. Thus, appropriate levels of methionine in the culture media are required to maintain SAM levels and global DNA and histone methylation, which are important for the maintenance of pluripotency [126].

Recent findings by Vernardis and collaborators correlate changes in metabolism to the differential responses of hiPSCs and hESCS, after prolonged exposure to ROCK (Rho kinase) inhibitor [153]. ROCK inhibition enables maintenance of stem cell phenotype. The authors assessed the effect of ROCK inhibition on the metabolic characteristics of cells over a 96 hours (h) of culture period. Both hPSCs and hiPSCs showed downregulation of the methionine pathway following 12 h and 24 h exposure and upregulation after 48 h. This suggests that both hPSCs and hiPSCs lose their highly proliferative characteristics after exposure to ROCK inhibition and regain their proliferation potential following adaptation to the new culture conditions. Interestingly, though, no differences in the gene expression, protein levels and physiology of hESCs and hiPSCs were observed, a differential expression of metabolic regulators p53 and mTORC1 revealed the fluctuating state of metabolism. Collectively, these and other studies have revealed the importance of methionine metabolism in integrating extrinsic amino acid information with the intrinsic epigenomics and pluripotency state to determine the cell fate of PSCs [154157].

Acetyl-CoA

While the importance of metabolism on SAM levels and global methylation patterns has been studied in detail, the regulation of other key metabolites, such as acetyl-CoA, in PSCs and iPSCs needs additional investigation. Acetyl-CoA is not only a substrate for TCA cycle but it may serve for histone acetylation in PSCs for maintaining their pluripotency [158]. By performing a high resolution nuclear magnetic resonance experiment, Moussaieff and collaborators identified a metabolic transition marked by loss of acetyl-CoA that leads to histone deacetylation, during hPSC differentiation [159]. The lipogenic enzyme acetyl-CoA carboxylase has been found upregulated in iPSCs and their inhibition is linked to decreased reprogramming efficiency [160]. Likewise, chemical inhibition of histone deacetylases is shown to promote reprogramming of somatic cells to iPSCs [161]. These studies suggest that it is via shunting of pyruvate-cytosolic acetyl-CoA that glycolysis may contribute to pluripotency regulation [162].

A recent study reported that cytosolic acetyl-CoA, whichis produced through glycolysis and the pyruvate-derived citrate flux via ATP citrate lyase (ACLY) is inhibited during PSC differentiation [159]. Acetyl-CoA blocks histone deacetylation and stem cell differentiation, while acetate, an alternative precursor of cytosolic acetyl-CoA, delays PSC differentiation by promoting histone acetylation in a dose-dependent fashion [159].Thus, a glycolytic switch that regulates histone acetylation can have a profound effect on the ability of stem cells to differentiate [159]. Of note, the decrease in OXPHOS might be causal for the activation of glycolysis during reprogramming, as (OXPHOS-derived) ATP is a potent allosteric inhibitor of a number of enzymes involved in glycolysis [163]. In sum, glycolysis may remodel the metabolome and facilitate the reprogramming of somatic cells into iPSCs [129, 164, 165].

While it is conventionally thought that metabolism is altered as a consequence of the chosen cell fate (i.e., metabolic demand drives the cell's metabolic program), an intriguing possibility is that metabolism itself can dictate stem cell renewal and/or differentiation by altering transcriptional networks that modulate cell fate [134]. It will be interesting to determine when during reprogramming and differentiation these metabolic changes take place. Characterization of the temporal regulation of metabolism, mitochondrial dynamics, and apoptosis during stem cell fate decisions could provide critical insight into if the changes in these processes are a result of the stem cell state, or a necessary factor for maintenance of the state of the cell.

CONCLUDING REMARKS

Mitochondria are a crucial source for fuel and intermediate metabolites that are essential for many cellular functions. These organelles house key proteins involved in the regulation of apoptosis and metabolism while maintaining a highly dynamic network that is essential for their function. Decades of studying these organelles in isolation have allowed for the elucidation of the main components involved in apoptosis, OXPHOS and mitochondrial dynamics, but we know less about the crosstalk between these pathways and how they are regulated as mitochondria communicate within themselves and with other cellular membranes. Many questions about mechanisms and integration of these mitochondrial changes and signaling networks remain unanswered. Future studies should be aimed to understand how these pathways intersect to regulate cell survival, what factors control the switch in mitochondrial network status, turnover, and connectivity to the ER as cells undergo reprogramming; how do changes in metabolic state and metabolite levels affect epigenetic enzymes that regulate gene expression; and how is respiratory capacity increased with differentiation and lowered with reprogramming. Answering these questions could lead to a complete understanding of how mitochondrial biology and function modulate cell fate.

Recent advances in the field of stem cell biology and in cellular reprogramming technology in particular, have created new opportunities in understanding human disease, drug discovery, and regenerative medicine. The generation of iPSCs reveals the remarkable plasticity associated with differentiated cells and provides unprecedented opportunity to model diseases using patient samples. In addition to transcriptional and epigenetic remodeling, cellular reprogramming is also accompanied by dramatic changes in the structure and function of the mitochondria. In this review, we describe three main mitochondrial events linked with reprogramming: increase of cell death sensitivity, fission of mitochondrial network, and decreased OXPHOS. We discussed potential mechanisms underlying the rewiring of the cellular state. It is clear, that we are just beginning to understand the integral roles played by mitochondrial morphology and function in development and diseases. There are also other areas of exciting opportunities. Today, it is possible to culture additional types of human pluripotent stem cells that model cells from preimplantation and post-implantation embryos [125, 166]. These different phases of pluripotency, for example, naïve state (which resembles the pre-implantation blastocyst inner cell mass), primed state (which resemble the post-implantation epiblast cells) and extended PSCs (which can generate embryonic and extraembryonic tissues), can all now be cultured in vitro simply by adapting different cell culture parameters. This possibility opens the potential to examine the function of mitochondrial morphology, dynamics and function in the context of the developmental potential of all of these model systems.

Pioneer work from Ruth Slack's group [11] highlighted the physiological significance of mitochondrial dynamics for stem cell identity and fate during mouse brain development. Studies in human brain have been limited by the lack of model systems. The emergence of three-dimensional models, known as organoids [167170], has opened a new avenue of discovery and could provide an additional model system to study the effects of disrupting mitochondrial morphology/function on early human brain development. While human stem cells provide many advantages, it is difficult to model many stages of maturation, such as neurodevelopmental processes of myelination, gliogenesis etc., which may not occur in the time that a monolayer culture can be maintained. Understanding the molecular events governing the mitochondria-related hallmarks described in this review, in the context of three-dimensional tissues could reveal new areas of discovery on the impact of disrupting mitochondrial function in the development of degenerative diseases. Organoids better recapitulate functional, structural, and architectural complexity of organs and their cellular diversity and thus, provide a powerful tool to dissect the principles of mitochondrial biology we have learned from other systems.

Recent discoveries have evidenced the interplay between mitochondrial dynamics, intermediate metabolism and epigenetics, thus, the traditional views of mitochondria as isolated organelles and of metabolism as a developmental byproduct have largely been refuted. To what extent mitochondrial morphology and cellular metabolism are directly wired to cellular transitions associated with development and reprograming warrants future investigations. Recent studies shed light into the essential requirement for a fine-tuned regulation of mitochondrial morphology and function for the maintenance of stem cell properties. New studies in these areas could have farreaching implications facilitating innovations leading to new treatments for patients affected by neurodevelopmental and neuropsychiatric disorders.

Acknowledgments

We sincerely apologize to colleagues whose work has not been included in this review due to space limitations. We would like to thank Natalya Ortolano for edits and comments to this manuscript and all members of the Gama laboratory for their experimental and conceptual contributions, which led to some of the ideas presented in this review. We especially thank Megan Rasmussen for the design of all the illustrations used in this review.

This work was supported by NIH Grants: 5R00CA178190-05 (to VG), 1R35GM128915-01 (to VG), 1R21CA227483-01A1 (to VG) and 5T32ES007028-44 (to PJ).

Abbreviatons

BAK

BCL-2 antagonist killer

BAX

BCL-2 associated X

BCL-2

B-Cell Lymphoma-2

BID

BCL-2 interacting domain death agonist

DRP

dynamin-related GTPase protein

ER

endoplasmic reticulum

ESC

embryonic stem cell

hPSC

human PSC

iPSC

induced PSC

OXPHOS

oxidative phosphorylation

PSC

pluripotent stem cell

ROCK

Rho kinase

ROS

reactive oxygen species

SAM

S-adenosylmethionine

TCA

tricarboxylic acid

REFERENCES

  • 1.Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell. 1996;86(1):147–157. doi: 10.1016/s0092-8674(00)80085-9. [DOI] [PubMed] [Google Scholar]
  • 2.Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988;335(6189):440–442. doi: 10.1038/335440a0. [DOI] [PubMed] [Google Scholar]
  • 3.Mishra P, Chan DC. Metabolic regulation of mitochondrial dynamics. J Cell Biol. 2016;212(4):379–387. doi: 10.1083/jcb.201511036. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Mishra P, Chan DC. Mitochondrial dynamics and inheritance during cell division, development and disease. Nat Rev Mol Cell Biol. 2014;15(10):634–646. doi: 10.1038/nrm3877. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Chauhan A, Vera J, Wolkenhauer O. The systems biology of mitochondrial fission and fusion and implications for disease and aging. Biogerontology. 2014;15(1):1–12. doi: 10.1007/s10522-013-9474-z. [DOI] [PubMed] [Google Scholar]
  • 6.Burté F, Carelli V, Chinnery PF, Yu-Wai-Man P. Disturbed mitochondrial dynamics and neurodegenerative disorders. Nat Rev Neurol. 2015;11(1):11–24. doi: 10.1038/nrneurol.2014.228. [DOI] [PubMed] [Google Scholar]
  • 7.Suen D-F, Norris KL, Youle RJ. Mitochondrial dynamics and apoptosis. Genes Dev. 2008;22(12):1577–1590. doi: 10.1101/gad.1658508. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Youle RJ, van der, Bliek AM. Mitochondrial fission, fusion, and stress. Science. 2012;337(6098):1062–1065. doi: 10.1126/science.1219855. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Elkholi R, Floros KV, Chipuk JE. The Role of BH3-Only Proteins in Tumor Cell Development, Signaling, and Treatment. Genes Cancer. 2011;2(5):523–537. doi: 10.1177/1947601911417177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Rasmussen ML, Kline LA, Park KP, Ortolano NA, Romero-Morales AI, Anthony CC, Beckermann KE, Gama V. A Non-apoptotic Function of MCL-1 in Promoting Pluripotency and Modulating Mitochondrial Dynamics in Stem Cells. Stem Cell Reports. 2018;10(3):684–692. doi: 10.1016/j.stemcr.2018.01.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Khacho M, Clark A, Svoboda DS, MacLaurin JG, Lagace DC, Park DS, Slack RS. Mitochondrial dysfunction underlies cognitive defects as a result of neural stem cell depletion and impaired neurogenesis. Hum Mol Genet. 2017;26(17):3327–3341. doi: 10.1093/hmg/ddx217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Salisbury-Ruf CT, Bertram CC, Vergeade A, Lark DS, Shi Q, Heberling ML, Fortune NL, Okoye GD, Jerome WG, Wells QS, Fessel J, Moslehi J, Chen H, Roberts LJ, Boutaud O, Gamazon ER, Zinkel SS. Bid maintains mitochondrial cristae structure and function and protects against cardiac disease in an integrative genomics study. Elife. 2018;7:e40907. doi: 10.7554/eLife.40907. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282(5391):1145–1147. doi: 10.1126/science.282.5391.1145. [DOI] [PubMed] [Google Scholar]
  • 14.Dumitru R, Gama V, Fagan BM, Bower JJ, Swahari V, Pevny LH, Deshmukh M. Human embryonic stem cells have constitutively active Bax at the Golgi and are primed to undergo rapid apoptosis. Mol Cell. 2012;46(5):573–583. doi: 10.1016/j.molcel.2012.04.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Liu JC, Guan X, Ryan JA, Rivera AG, Mock C, Agrawal V, Agarwal V, Letai A, Lerou PH, Lahav G. High mitochondrial priming sensitizes hESCs to DNA-damage-induced apoptosis. Cell Stem Cell. 2013;13(4):483–491. doi: 10.1016/j.stem.2013.07.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Mathieu J, Ruohola-Baker H. Metabolic remodeling during the loss and acquisition of pluripotency. Development. 2017;144(4):541–551. doi: 10.1242/dev.128389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Mishra P, Chan DC. Mitochondrial dynamics and inheritance during cell division, development and disease. Nat Rev Mol Cell Biol. 2014;15(10):634–646. doi: 10.1038/nrm3877. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26(4):239–257. doi: 10.1038/bjc.1972.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Wong RSY. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 2011;30:87. doi: 10.1186/1756-9966-30-87. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Schimmer AD. Apoptosis in leukemia: from molecular pathways to targeted therapies. Best Pract Res Clin Haematol. 2008;21(1):5–11. doi: 10.1016/j.beha.2007.11.002. [DOI] [PubMed] [Google Scholar]
  • 21.Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495–516. doi: 10.1080/01926230701320337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Ashkenazi A, Dixit VM. Death Receptors: Signaling and Modulation. Science. 1998;281(5381):1305–1308. doi: 10.1126/science.281.5381.1305. [DOI] [PubMed] [Google Scholar]
  • 23.Mehlen P, Bredesen DE. Dependence receptors: from basic research to drug development. Sci Signal. 2011;4(157):mr2. doi: 10.1126/scisignal.2001521. [DOI] [PubMed] [Google Scholar]
  • 24.Galluzzi L, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25(3):486–541. doi: 10.1038/s41418-017-0012-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. Cell. 2009;137(3):413–431. doi: 10.1016/j.cell.2009.04.037. [DOI] [PubMed] [Google Scholar]
  • 26.Tiwari B, Jones AE, Abrams JM. Transposons, p53 and Genome Security. Trends Genet. 2018;34(11):846–855. doi: 10.1016/j.tig.2018.08.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG, Youle RJ. Movement of Bax from the cytosol to mitochondria during apoptosis. J Cell Biol. 1997;139(5):1281–1292. doi: 10.1083/jcb.139.5.1281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Walensky LD, Gavathiotis E. BAX unleashed: the biochemical transformation of an inactive cytosolic monomer into a toxic mitochondrial pore. Trends Biochem Sci. 2011;36(12):642–652. doi: 10.1016/j.tibs.2011.08.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, Green DR. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science. 2004;303(5660):1010–1014. doi: 10.1126/science.1092734. [DOI] [PubMed] [Google Scholar]
  • 30.Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004;116(2):205–219. doi: 10.1016/S0092-8674(04)00046-7. [DOI] [PubMed] [Google Scholar]
  • 31.Chipuk JE, Green DR. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol. 2008;18(4):157–164. doi: 10.1016/j.tcb.2008.01.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9(1):47–59. doi: 10.1038/nrm2308. [DOI] [PubMed] [Google Scholar]
  • 33.Llambi F, Moldoveanu T, Tait SWG, Bouchier-Hayes L, Temirov J, McCormick LL, Dillon CP, Green DR. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol Cell. 2011;44(4):517–531. doi: 10.1016/j.molcel.2011.10.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Opferman JT, Kothari A. Anti-apoptotic BCL-2 family members in development. Cell Death Differ. 2018;25(1):37–45. doi: 10.1038/cdd.2017.170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Brunelle JK, Letai A. Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci. 2009;122(Pt 4):437–441. doi: 10.1242/jcs.031682. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, Piao H, Horowitz NS, Berkowitz RS, Matulonis U, Jänne PA, Amrein PC, Cichowski K, Drapkin R, Letai A. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 2015;160(5):977–989. doi: 10.1016/j.cell.2015.01.042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Montero J, Letai A. Dynamic BH3 profiling-poking cancer cells with a stick. Mol Cell Oncol. 2016;3(3):e1040144. doi: 10.1080/23723556.2015.1040144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Belizário JE, Alves J, Occhiucci JM, Garay-Malpartida M, Sesso A. A mechanistic view of mitochondrial death decision pores. Braz J Med Biol Res. 2007;40(8):1011–1024. doi: 10.1590/s0100-879x2006005000109. [DOI] [PubMed] [Google Scholar]
  • 39.Inoue S, Browne G, Melino G, Cohen GM. Ordering of caspases in cells undergoing apoptosis by the intrinsic pathway. Cell Death Differ. 2009;16(7):1053–1061. doi: 10.1038/cdd.2009.29. [DOI] [PubMed] [Google Scholar]
  • 40.Kim H-E, Du F, Fang M, Wang X. Formation of apoptosome is initiated by cytochrome c-induced dATP hydrolysis and subsequent nucleotide exchange on Apaf-1. Proc Natl Acad Sci USA. 2005;102(49):17545–17550. doi: 10.1073/pnas.0507900102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol. 2008;9(3):231–241. doi: 10.1038/nrm2312. [DOI] [PubMed] [Google Scholar]
  • 42.Ramirez MLG, Salvesen GS. A primer on caspase mechanisms. Semin Cell Dev Biol. 2018;82:79–85. doi: 10.1016/j.semcdb.2018.01.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Fuchs Y, Steller H. Programmed cell death in animal development and disease. Cell. 2011;147(4):742–758. doi: 10.1016/j.cell.2011.10.033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Gama V, Deshmukh M. Human embryonic stem cells: living on the edge. Cell Cycle. 2012;11(21):3905–3906. doi: 10.4161/cc.22233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Stambrook PJ, Tichy ED. Preservation of genomic integrity in mouse embryonic stem cells. Adv Exp Med Biol. 2010;695:59–75. doi: 10.1007/978-1-4419-7037-4_5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Brosh R, Assia-Alroy Y, Molchadsky A, Bornstein C, Dekel E, Madar S, Shetzer Y, Rivlin N, Goldfinger N, Sarig R, Rotter V. p53 counteracts reprogramming by inhibiting mesenchymal-to-epithelial transition. Cell Death Differ. 2013;20(2):312–320. doi: 10.1038/cdd.2012.125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Ohgushi M, Matsumura M, Eiraku M, Murakami K, Aramaki T, Nishiyama A, Muguruma K, Nakano T, Suga H, Ueno M, Ishizaki T, Suemori H, Narumiya S, Niwa H, Sasai Y. Molecular pathway and cell state responsible for dissociation-induced apoptosis in human pluripotent stem cells. Cell Stem Cell. 2010;7(2):225–239. doi: 10.1016/j.stem.2010.06.018. [DOI] [PubMed] [Google Scholar]
  • 48.Hanna J, Saha K, Pando B, van Zon J, Lengner CJ, Creyghton MP, van Oudenaarden A, Jaenisch R. Direct cell reprogramming is a stochastic process amenable to acceleration. Nature. 2009;462(7273):595–601. doi: 10.1038/nature08592. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M, Okita K, Yamanaka S. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature. 2009;460(7259):1132–1135. doi: 10.1038/nature08235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Kawamura T, Suzuki J, Wang YV, Menendez S, Morera LB, Raya A, Wahl GM, Izpisúa Belmonte JC. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature. 2009;460(7259):1140–1144. doi: 10.1038/nature08311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Sakamaki K, Inoue T, Asano M, Sudo K, Kazama H, Sakagami J, Sakata S, Ozaki M, Nakamura S, Toyokuni S, Osumi N, Iwakura Y, Yonehara S. Ex vivo whole-embryo culture of caspase-8-deficient embryos normalize their aberrant phenotypes in the developing neural tube and heart. Cell Death Differ. 2002;9(11):1196–1206. doi: 10.1038/sj.cdd.4401090. [DOI] [PubMed] [Google Scholar]
  • 52.Fujita J, Crane AM, Souza MK, Dejosez M, Kyba M, Flavell RA, Thomson JA, Zwaka TP. Caspase activity mediates the differentiation of embryonic stem cells. Cell Stem Cell. 2008;2(6):595–601. doi: 10.1016/j.stem.2008.04.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Wang X, Lin G, Martins-Taylor K, Zeng H, Xu R-H. Inhibition of caspase-mediated anoikis is critical for basic fibroblast growth factor-sustained culture of human pluripotent stem cells. J Biol Chem. 2009;284(49):34054–34064. doi: 10.1074/jbc.M109.052290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Li F, He Z, Shen J, Huang Q, Li W, Liu X, He Y, Wolf F, Li C-Y. Apoptotic caspases regulate induction of iPSCs from human fibroblasts. Cell Stem Cell. 2010;7(4):508–520. doi: 10.1016/j.stem.2010.09.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Jain AK, Barton MC. p53: emerging roles in stem cells, development and beyond. Development. 2018;145(8):dev158360. doi: 10.1242/dev.158360. [DOI] [PubMed] [Google Scholar]
  • 56.Akdemir KC, Jain AK, Allton K, Aronow B, Xu X, Cooney AJ, Li W, Barton MC. Genome-wide profiling reveals stimulusspecific functions of p53 during differentiation and DNA damage of human embryonic stem cells. Nucleic Acids Res. 2014;42(1):205–223. doi: 10.1093/nar/gkt866. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Li M, He Y, Dubois W, Wu X, Shi J, Huang J. Distinct regulatory mechanisms and functions for p53-activated and p53-repressed DNA damage response genes in embryonic stem cells. Mol Cell. 2012;46(1):30–42. doi: 10.1016/j.molcel.2012.01.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Liu Y, Elf SE, Miyata Y, Sashida G, Liu Y, Huang G, Di Giandomenico S, Lee JM, Deblasio A, Menendez S, Antipin J, Reva B, Koff A, Nimer SD. p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell. 2009;4(1):37–48. doi: 10.1016/j.stem.2008.11.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Meletis K, Wirta V, Hede S-M, Nistér M, Lundeberg J, Frisén J. p53 suppresses the self-renewal of adult neural stem cells. Development. 2006;133(2):363–369. doi: 10.1242/dev.02208. [DOI] [PubMed] [Google Scholar]
  • 60.Setoguchi K, TeSlaa T, Koehler CM, Teitell MA. P53 Regulates Rapid Apoptosis in Human Pluripotent Stem Cells. J Mol Biol. 2016;428(7):1465–1475. doi: 10.1016/j.jmb.2015.07.019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Maimets T, Neganova I, Armstrong L, Lako M. Activation of p53 by nutlin leads to rapid differentiation of human embryonic stem cells. Oncogene. 2008;27(40):5277–5287. doi: 10.1038/onc.2008.166. [DOI] [PubMed] [Google Scholar]
  • 62.Utikal J, Polo JM, Stadtfeld M, Maherali N, Kulalert W, Walsh RM, Khalil A, Rheinwald JG, Hochedlinger K. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature. 2009;460(7259):1145–1148. doi: 10.1038/nature08285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Marión RM, Strati K, Li H, Murga M, Blanco R, Ortega S, Fernandez-Capetillo O, Serrano M, Blasco MA. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature. 2009;460(7259):1149–1153. doi: 10.1038/nature08287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Choi YJ, Lin C-P, Ho JJ, He X, Okada N, Bu P, Zhong Y, Kim SY, Bennett MJ, Chen C, Ozturk A, Hicks GG, Hannon GJ, He L. miR-34 miRNAs provide a barrier for somatic cell reprogramming. Nat Cell Biol. 2011;13(11):1353–1360. doi: 10.1038/ncb2366. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Kim EJY, Anko M-L, Flensberg C, Majewski IJ, Geng F-S, Firas J, Huang DCS, van Delft MF, Heath JK. BAK/BAX-Mediated Apoptosis Is a Myc-Induced Roadblock to Reprogramming. Stem Cell Reports. 2018;10(2):331–338. doi: 10.1016/j.stemcr.2017.12.019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Li Y, Feng H, Gu H, Lewis DW, Yuan Y, Zhang L, Yu H, Zhang P, Cheng H, Miao W, Yuan W, Cheng S-Y, Gollin SM, Cheng T. The p53-PUMA axis suppresses iPSC generation. Nat Commun. 2013;4:2174. doi: 10.1038/ncomms3174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W, Wang R, Green DR, Tessarollo L, Casellas R, Zhao K, Levens D. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell. 2012;151(1):68–79. doi: 10.1016/j.cell.2012.08.033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Polo JM, Anderssen E, Walsh RM, Schwarz BA, Nefzger CM, Lim SM, Borkent M, Apostolou E, Alaei S, Cloutier J, Bar-Nur O, Cheloufi S, Stadtfeld M, Figueroa ME, Robinton D, Natesan S, Melnick A, Zhu J, Ramaswamy S, Hochedlinger K. A molecular roadmap of reprogramming somatic cells into iPS cells. Cell. 2012;151(7):1617–1632. doi: 10.1016/j.cell.2012.11.039. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Banáth JP, Bañuelos CA, Klokov D, MacPhail SM, Lansdorp PM, Olive PL. Explanation for excessive DNA single-strand breaks and endogenous repair foci in pluripotent mouse embryonic stem cells. Exp Cell Res. 2009;315(8):1505–1520. doi: 10.1016/j.yexcr.2008.12.007. [DOI] [PubMed] [Google Scholar]
  • 70.Lewis MR, Lewis WH. Mitochondria in Tissue Culture. Science. 1914;39(1000):330–333. doi: 10.1126/science.39.1000.330. [DOI] [PubMed] [Google Scholar]
  • 71.Johnson LV, Walsh ML, Bockus BJ, Chen LB. Monitoring of relative mitochondrial membrane potential in living cells by fluorescence microscopy. J Cell Biol. 1981;88(3):526–535. doi: 10.1083/jcb.88.3.526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Bereiter-Hahn J, Vöth M. Dynamics of mitochondria in living cells: shape changes, dislocations, fusion, and fission of mitochondria. Microsc Res Tech. 1994;27(3):198–219. doi: 10.1002/jemt.1070270303. [DOI] [PubMed] [Google Scholar]
  • 73.Rizzuto R, Brini M, De Giorgi F, Rossi R, Heim R, Tsien RY, Pozzan T. Double labelling of subcellular structures with organelle-targeted GFP mutants in vivo. Curr Biol. 1996;6(2):183–188. doi: 10.1016/s0960-9822(02)00451-7. [DOI] [PubMed] [Google Scholar]
  • 74.Westermann B. Mitochondrial fusion and fission in cell life and death. Nat Rev Mol Cell Biol. 2010;11(12):872–884. doi: 10.1038/nrm3013. [DOI] [PubMed] [Google Scholar]
  • 75.Friedman JR, Nunnari J. Mitochondrial form and function. Nature. 2014;505(7483):335–343. doi: 10.1038/nature12985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Nunnari J, Suomalainen A. Mitochondria: In Sickness and in Health. Cell. 2012;148(6):1145–1159. doi: 10.1016/j.cell.2012.02.035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Chan DC. Fusion and fission: interlinked processes critical for mitochondrial health. Annu Rev Genet. 2012;46:265–287. doi: 10.1146/annurev-genet-110410-132529. [DOI] [PubMed] [Google Scholar]
  • 78.Facucho-Oliveira JM, St John JC. The relationship between pluripotency and mitochondrial DNA proliferation during early embryo development and embryonic stem cell differentiation. Stem Cell Rev. 2009;5(2):140–158. doi: 10.1007/s12015-009-9058-0. [DOI] [PubMed] [Google Scholar]
  • 79.Chung S, Arrell DK, Faustino RS, Terzic A, Dzeja PP. Glycolytic network restructuring integral to the energetics of embryonic stem cell cardiac differentiation. J Mol Cell Cardiol. 2010;48(4):725–734. doi: 10.1016/j.yjmcc.2009.12.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Hoppins S, Lackner L, Nunnari J. The machines that divide and fuse mitochondria. Annu Rev Biochem. 2007;76:751–780. doi: 10.1146/annurev.biochem.76.071905.090048. [DOI] [PubMed] [Google Scholar]
  • 81.Praefcke GJK, McMahon HT. The dynamin superfamily: universal membrane tubulation and fission molecules? Nat Rev Mol Cell Biol. 2004;5(2):133–147. doi: 10.1038/nrm1313. [DOI] [PubMed] [Google Scholar]
  • 82.Meglei G, McQuibban GA. The dynamin-related protein Mgm1p assembles into oligomers and hydrolyzes GTP to function in mitochondrial membrane fusion. Biochemistry. 2009;48(8):1774–1784. doi: 10.1021/bi801723d. [DOI] [PubMed] [Google Scholar]
  • 83.van der Bliek AM, Payne GS. Dynamin subunit interactions revealed. Dev Cell. 2010;18(5):687–688. doi: 10.1016/j.devcel.2010.05.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Chappie JS, Acharya S, Leonard M, Schmid SL, Dyda F. G domain dimerization controls dynamin's assembly-stimulated GTPase activity. Nature. 2010;465(7297):435–440. doi: 10.1038/nature09032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Gao S, von der Malsburg A, Paeschke S, Behlke J, Haller O, Kochs G, Daumke O. Structural basis of oligomerization in the stalk region of dynamin-like MxA. Nature. 2010;465(7297):502–506. doi: 10.1038/nature08972. [DOI] [PubMed] [Google Scholar]
  • 86.Mears JA, Lackner LL, Fang S, Ingerman E, Nunnari J, Hinshaw JE. Conformational changes in Dnm1 support a contractile mechanism for mitochondrial fission. Nat Struct Mol Biol. 2011;18(1):20–26. doi: 10.1038/nsmb.1949. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Frank S, Gaume B, Bergmann-Leitner ES, Leitner WW, Robert EG, Catez F, Smith CL, Youle RJ. The role of dynamin-related protein 1, a mediator of mitochondrial fission, in apoptosis. Dev Cell. 2001;1(4):515–525. doi: 10.1016/s1534-5807(01)00055-7. [DOI] [PubMed] [Google Scholar]
  • 88.Alexander C, Votruba M, Pesch UE, Thiselton DL, Mayer S, Moore A, Rodriguez M, Kellner U, Leo-Kottler B, Auburger G, Bhattacharya SS, Wissinger B. OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28. Nat Genet. 2000;26(2):211–215. doi: 10.1038/79944. [DOI] [PubMed] [Google Scholar]
  • 89.Delettre C, Lenaers G, Griffoin JM, Gigarel N, Lorenzo C, Belenguer P, Pelloquin L, Grosgeorge J, Turc-Carel C, Perret E, Astarie-Dequeker C, Lasquellec L, Arnaud B, Ducommun B, Kaplan J, Hamel CP. Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. Nat Genet. 2000;26(2):207–210. doi: 10.1038/79936. [DOI] [PubMed] [Google Scholar]
  • 90.Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J Cell Biol. 2003;160(2):189–200. doi: 10.1083/jcb.200211046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91.Misaka T, Miyashita T, Kubo Y. Primary structure of a dynamin-related mouse mitochondrial GTPase and its distribution in brain, subcellular localization, and effect on mitochondrial morphology. J Biol Chem. 2002;277(18):15834–15842. doi: 10.1074/jbc.M109260200. [DOI] [PubMed] [Google Scholar]
  • 92.Legros F, Lombès A, Frachon P, Rojo M. Mitochondrial fusion in human cells is efficient, requires the inner membrane potential, and is mediated by mitofusins. Mol Biol Cell. 2002;13(12):4343–4354. doi: 10.1091/mbc.e02-06-0330. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Meeusen S, McCaffery JM, Nunnari J. Mitochondrial fusion intermediates revealed in vitro. Science. 2004;305(5691):1747–1752. doi: 10.1126/science.1100612. [DOI] [PubMed] [Google Scholar]
  • 94.Labbé C, Rayaprolu S, Soto-Ortolaza A, Ogaki K, Uitti RJ, Wszolek ZK, Ross OA. Investigating FUS variation in Parkinson's disease. Parkinsonism Relat Disord. 2014;20(Suppl 1):S147–149. doi: 10.1016/S1353-8020(13)70035-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95.Davies VJ, Hollins AJ, Piechota MJ, Yip W, Davies JR, White KE, Nicols PP, Boulton ME, Votruba M. Opa1 deficiency in a mouse model of autosomal dominant optic atrophy impairs mitochondrial morphology, optic nerve structure and visual function. Hum Mol Genet. 2007;16(11):1307–1318. doi: 10.1093/hmg/ddm079. [DOI] [PubMed] [Google Scholar]
  • 96.Alavi MV, Bette S, Schimpf S, Schuettauf F, Schraermeyer U, Wehrl HF, Ruttiger L, Beck SC, Tonagel F, Pichler BJ, Knipper M, Peters T, Laufs J, Wissinger B. A splice site mutation in the murine Opa1 gene features pathology of autosomal dominant optic atrophy. Brain. 2007;130(Pt 4):1029–1042. doi: 10.1093/brain/awm005. [DOI] [PubMed] [Google Scholar]
  • 97.Ishihara N, Nomura M, Jofuku A, Kato H, Suzuki SO, Masuda K, Otera H, Nakanishi Y, Nonaka I, Goto Y-I, Taguchi N, Morinaga H, Maeda M, Takayanagi R, Yokota S, Mihara K. Mitochondrial fission factor Drp1 is essential for embryonic development and synapse formation in mice. Nat Cell Biol. 2009;11(8):958–966. doi: 10.1038/ncb1907. [DOI] [PubMed] [Google Scholar]
  • 98.Waterham HR, Koster J, van Roermund CWT, Mooyer PAW, Wanders RJA, Leonard JV. A lethal defect of mitochondrial and peroxisomal fission. N Engl J Med. 2007;356(17):1736–1741. doi: 10.1056/NEJMoa064436. [DOI] [PubMed] [Google Scholar]
  • 99.Züchner S, Mersiyanova IV, Muglia M, Bissar-Tadmouri N, Rochelle J, Dadali EL, Zappia M, Nelis E, Patitucci A, Senderek J, Parman Y, Evgrafov O, Jonghe PD, Takahashi Y, Tsuji S, Pericak-Vance MA, Quattrone A, Battaloglu E, Polyakov AV, Timmerman V, Schröder JM, Vance JM, Battologlu E. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet. 2004;36(5):449–451. doi: 10.1038/ng1341. [DOI] [PubMed] [Google Scholar]
  • 100.Cleland J, Gillani R, Bienen EJ, Sadosky A. Assessing dimensionality and responsiveness of outcomes measures for patients with low back pain. Pain Pract. 2011;11(1):57–69. doi: 10.1111/j.1533-2500.2010.00390.x. [DOI] [PubMed] [Google Scholar]
  • 101.Karbowski M, Norris KL, Cleland MM, Jeong S-Y, Youle RJ. Role of Bax and Bak in mitochondrial morphogenesis. Nature. 2006;443(7112):658–662. doi: 10.1038/nature05111. [DOI] [PubMed] [Google Scholar]
  • 102.Hoppins S, Edlich F, Cleland MM, Banerjee S, McCaffery JM, Youle RJ, Nunnari J. The soluble form of Bax regulates mitochondrial fusion via MFN2 homotypic complexes. Mol Cell. 2011;41(2):150–160. doi: 10.1016/j.molcel.2010.11.030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.Brooks C, Wei Q, Feng L, Dong G, Tao Y, Mei L, Xie Z-J, Dong Z. Bak regulates mitochondrial morphology and pathology during apoptosis by interacting with mitofusins. Proc Natl Acad Sci USA. 2007;104(28):11649–11654. doi: 10.1073/pnas.0703976104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 104.Chen Y-B, Aon MA, Hsu Y-T, Soane L, Teng X, McCaffery JM, Cheng W-C, Qi B, Li H, Alavian KN, Dayhoff-Brannigan M, Zou S, Pineda FJ, O'Rourke B, Ko YH, Pedersen PL, Kaczmarek LK, Jonas EA, Hardwick JM. Bcl-xL regulates mitochondrial energetics by stabilizing the inner membrane potential. J Cell Biol. 2011;195(2):263–276. doi: 10.1083/jcb.201108059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 105.Berman SB, Pineda FJ, Hardwick JM. Mitochondrial fission and fusion dynamics: the long and short of it. Cell Death Differ. 2008;15(7):1147–1152. doi: 10.1038/cdd.2008.57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106.Li H, Chen Y, Jones AF, Sanger RH, Collis LP, Flannery R, McNay EC, Yu T, Schwarzenbacher R, Bossy B, Bossy-Wetzel E, Bennett MVL, Pypaert M, Hickman JA, Smith PJS, Hardwick JM, Jonas EA. Bcl-xL induces Drp1-dependent synapse formation in cultured hippocampal neurons. Proc Natl Acad Sci USA. 2008;105(6):2169–2174. doi: 10.1073/pnas.0711647105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 107.Karbowski M, Lee Y-J, Gaume B, Jeong S-Y, Frank S, Nechushtan A, Santel A, Fuller M, Smith CL, Youle RJ. Spatial and temporal association of Bax with mitochondrial fission sites, Drp1, and Mfn2 during apoptosis. J Cell Biol. 2002;159(6):931–938. doi: 10.1083/jcb.200209124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108.Kushnareva Y, Andreyev AY, Kuwana T, Newmeyer DD. Bax activation initiates the assembly of a multimeric catalyst that facilitates Bax pore formation in mitochondrial outer membranes. PLoS Biol. 2012;10(9):e1001394. doi: 10.1371/journal.pbio.1001394. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 109.Colell A, Ricci J-E, Tait S, Milasta S, Maurer U, Bouchier-Hayes L, Fitzgerald P, Guio-Carrion A, Waterhouse NJ, Li CW, Mari B, Barbry P, Newmeyer DD, Beere HM, Green DR. GAPDH and autophagy preserve survival after apoptotic cytochrome c release in the absence of caspase activation. Cell. 2007;129(5):983–997. doi: 10.1016/j.cell.2007.03.045. [DOI] [PubMed] [Google Scholar]
  • 110.Ekert PG, Read SH, Silke J, Marsden VS, Kaufmann H, Hawkins CJ, Gerl R, Kumar S, Vaux DL. Apaf-1 and caspase-9 accelerate apoptosis, but do not determine whether factor-deprived or drugtreated cells die. J Cell Biol. 2004;165(6):835–842. doi: 10.1083/jcb.200312031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 111.Ow Y-LP, Green DR, Hao Z, Mak TW. Cytochrome c: functions beyond respiration. Nat Rev Mol Cell Biol. 2008;9(7):532–542. doi: 10.1038/nrm2434. [DOI] [PubMed] [Google Scholar]
  • 112.Goldstein JC, Waterhouse NJ, Juin P, Evan GI, Green DR. The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Nat Cell Biol. 2000;2(3):156–162. doi: 10.1038/35004029. [DOI] [PubMed] [Google Scholar]
  • 113.Yamaguchi R, Lartigue L, Perkins G, Scott RT, Dixit A, Kushnareva Y, Kuwana T, Ellisman MH, Newmeyer DD. Opa1-mediated cristae opening is Bax/Bak and BH3 dependent, required for apoptosis, and independent of Bak oligomerization. Mol Cell. 2008;31(4):557–569. doi: 10.1016/j.molcel.2008.07.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 114.Cogliati S, Enriquez JA, Scorrano L. Mitochondrial Cristae: Where Beauty Meets Functionality. Trends Biochem Sci. 2016;41(3):261–273. doi: 10.1016/j.tibs.2016.01.001. [DOI] [PubMed] [Google Scholar]
  • 115.Kuwana T, Mackey MR, Perkins G, Ellisman MH, Latterich M, Schneiter R, Green DR, Newmeyer DD. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell. 2002;111(3):331–342. doi: 10.1016/s0092-8674(02)01036-x. [DOI] [PubMed] [Google Scholar]
  • 116.Montessuit S, Somasekharan SP, Terrones O, Lucken-Ardjomande S, Herzig S, Schwarzenbacher R, Manstein DJ, Bossy-Wetzel E, Basañez G, Meda P, Martinou J-C. Membrane remodeling induced by the dynamin-related protein Drp1 stimulates Bax oligomerization. Cell. 2010;142(6):889–901. doi: 10.1016/j.cell.2010.08.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 117.Sinibaldi F, Howes BD, Droghetti E, Polticelli F, Piro MC, Di Pierro D, Fiorucci L, Coletta M, Smulevich G, Santucci R. Role of lysines in cytochrome c-cardiolipin interaction. Biochemistry. 2013;52(26):4578–4588. doi: 10.1021/bi400324c. [DOI] [PubMed] [Google Scholar]
  • 118.Gao W, Pu Y, Luo KQ, Chang DC. Temporal relationship between cytochrome c release and mitochondrial swelling during UV-induced apoptosis in living HeLa cells. J Cell Sci. 2001;114(Pt 15):2855–2862. doi: 10.1242/jcs.114.15.2855. [DOI] [PubMed] [Google Scholar]
  • 119.Lee Y, Jeong S-Y, Karbowski M, Smith CL, Youle RJ. Roles of the mammalian mitochondrial fission and fusion mediators Fis1, Drp1, and Opa1 in apoptosis. Mol Biol Cell. 2004;15(11):5001–5011. doi: 10.1091/mbc.e04-04-0294. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 120.Sheridan C, Delivani P, Cullen SP, Martin SJ. Bax- or Bak-induced mitochondrial fission can be uncoupled from cytochrome C release. Mol Cell. 2008;31(4):570–585. doi: 10.1016/j.molcel.2008.08.002. [DOI] [PubMed] [Google Scholar]
  • 121.Estaquier J, Arnoult D. Inhibiting Drp1-mediated mitochondrial fission selectively prevents the release of cytochrome c during apoptosis. Cell Death Differ. 2007;14(6):1086–1094. doi: 10.1038/sj.cdd.4402107. [DOI] [PubMed] [Google Scholar]
  • 122.Sugioka R, Shimizu S, Tsujimoto Y. Fzo1, a protein involved in mitochondrial fusion, inhibits apoptosis. J Biol Chem. 2004;279(50):52726–52734. doi: 10.1074/jbc.M408910200. [DOI] [PubMed] [Google Scholar]
  • 123.Karbowski M, Jeong S-Y, Youle RJ. Endophilin B1 is required for the maintenance of mitochondrial morphology. J Cell Biol. 2004;166(7):1027–1039. doi: 10.1083/jcb.200407046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 124.Friedman JR, Lackner LL, West M, DiBenedetto JR, Nunnari J, Voeltz GK. ER tubules mark sites of mitochondrial division. Science. 2011;334(6054):358–362. doi: 10.1126/science.1207385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 125.Zhang J, Zhao J, Dahan P, Lu V, Zhang C, Li H, Teitell MA. Metabolism in Pluripotent Stem Cells and Early Mammalian Development. Cell Metabolism. 2018;27(2):332–338. doi: 10.1016/j.cmet.2018.01.008. [DOI] [PubMed] [Google Scholar]
  • 126.Teslaa T, Teitell MA. Pluripotent stem cell energy metabolism: an update. EMBO J. 2015;34(2):138–153. doi: 10.15252/embj.201490446. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 127.Zhou W, Choi M, Margineantu D, Margaretha L, Hesson J, Cavanaugh C, Blau CA, Horwitz MS, Hockenbery D, Ware C, Ruohola-Baker H. HIF1α induced switch from bivalent to exclusively glycolytic metabolism during ESC-to-EpiSC/hESC transition. EMBO J. 2012;31(9):2103–2116. doi: 10.1038/emboj.2012.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 128.Xu X, Duan S, Yi F, Ocampo A, Liu G-H, Izpisua Belmonte JC. Mitochondrial Regulation in Pluripotent Stem Cells. Cell Metabolism. 2013;18(3):325–332. doi: 10.1016/j.cmet.2013.06.005. [DOI] [PubMed] [Google Scholar]
  • 129.Varum S, Rodrigues AS, Moura MB, Momcilovic O, Easley CA, Ramalho-Santos J, Van Houten B, Schatten G. Energy metabolism in human pluripotent stem cells and their differentiated counterparts. PLoS ONE. 2011;6(6):e20914. doi: 10.1371/journal.pone.0020914. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 130.Folmes CDL, Dzeja PP, Nelson TJ, Terzic A. Metabolic plasticity in stem cell homeostasis and differentiation. Cell Stem Cell. 2012;11(5):596–606. doi: 10.1016/j.stem.2012.10.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 131.Chen X, Gu Q, Wang X, Ma Q, Tang H, Yan X, Guo X, Yan H, Hao J, Zeng F. Directed neuronal differentiation of mouse embryonic and induced pluripotent stem cells and their gene expression profiles. Int J Mol Med. 2013;32(1):25–34. doi: 10.3892/ijmm.2013.1372. [DOI] [PubMed] [Google Scholar]
  • 132.Sena LA, Chandel NS. Physiological roles of mitochondrial reactive oxygen species. Mol Cell. 2012;48(2):158–167. doi: 10.1016/j.molcel.2012.09.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 133.Zhang J, Khvorostov I, Hong JS, Oktay Y, Vergnes L, Nuebel E, Wahjudi PN, Setoguchi K, Wang G, Do A, Jung H-J, McCaffery JM, Kurland IJ, Reue K, Lee W-NP, Koehler CM, Teitell MA. UCP2 regulates energy metabolism and differentiation potential of human pluripotent stem cells. EMBO J. 2016;35(8):899. doi: 10.15252/embj.201694054. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 134.Chandel NS. Evolution of Mitochondria as Signaling Organelles. Cell Metab. 2015;22(2):204–206. doi: 10.1016/j.cmet.2015.05.013. [DOI] [PubMed] [Google Scholar]
  • 135.DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2(5):e1600200. doi: 10.1126/sciadv.1600200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 136.Chandel NS. Mitochondria as signaling organelles. BMC Biol. 2014;12:34. doi: 10.1186/1741-7007-12-34. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 137.Picard M, Wallace DC, Burelle Y. The rise of mitochondria in medicine. Mitochondrion. 2016;30:105–116. doi: 10.1016/j.mito.2016.07.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 138.Wallace DC. Bioenergetics in human evolution and disease: implications for the origins of biological complexity and the missing genetic variation of common diseases. Philos Trans R Soc Lond, B, Biol Sci. 2013;368(1622):20120267. doi: 10.1098/rstb.2012.0267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 139.Gaspar JA, Doss MX, Hengstler JG, Cadenas C, Hescheler J, Sachinidis A. Unique metabolic features of stem cells, cardiomyocytes, and their progenitors. Circ Res. 2014;114(8):1346–1360. doi: 10.1161/CIRCRESAHA.113.302021. [DOI] [PubMed] [Google Scholar]
  • 140.Shyh-Chang N, Daley GQ, Cantley LC. Stem cell metabolism in tissue development and aging. Development. 2013;140(12):2535–2547. doi: 10.1242/dev.091777. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 141.Shyh-Chang N, Ng H-H. The metabolic programming of stem cells. Genes Dev. 2017;31(4):336–346. doi: 10.1101/gad.293167.116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 142.Burgess RJ, Agathocleous M, Morrison SJ. Metabolic regulation of stem cell function. J Intern Med. 2014;276(1):12–24. doi: 10.1111/joim.12247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 143.Ezashi T, Das P, Roberts RM. Low O2 tensions and the prevention of differentiation of hES cells. Proc Natl Acad Sci USA. 2005;102(13):4783–4788. doi: 10.1073/pnas.0501283102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 144.Prasad SM, Czepiel M, Cetinkaya C, Smigielska K, Weli SC, Lysdahl H, Gabrielsen A, Petersen K, Ehlers N, Fink T, Minger SL, Zachar V. Continuous hypoxic culturing maintains activation of Notch and allows long-term propagation of human embryonic stem cells without spontaneous differentiation. Cell Prolif. 2009;42(1):63–74. doi: 10.1111/j.1365-2184.2008.00571.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 145.Pattappa G, Thorpe SD, Jegard NC, Heywood HK, de Bruijn JD, Lee DA. Continuous and uninterrupted oxygen tension influences the colony formation and oxidative metabolism of human mesenchymal stem cells. Tissue Eng Part C Methods. 2013;19(1):68–79. doi: 10.1089/ten.TEC.2011.0734. [DOI] [PubMed] [Google Scholar]
  • 146.Goda N, Kanai M. Hypoxia-inducible factors and their roles in energy metabolism. Int J Hematol. 2012;95(5):457–463. doi: 10.1007/s12185-012-1069-y. [DOI] [PubMed] [Google Scholar]
  • 147.Mahato B, Home P, Rajendran G, Paul A, Saha B, Ganguly A, Ray S, Roy N, Swerdlow RH, Paul S. Regulation of mitochondrial function and cellular energy metabolism by protein kinase C-λ/ι: a novel mode of balancing pluripotency. Stem Cells. 2014;32(11):2880–2892. doi: 10.1002/stem.1817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 148.Pereira SL, Rodrigues AS, Sousa MI, Correia M, Perestrelo T, Ramalho-Santos J. From gametogenesis and stem cells to cancer: common metabolic themes. Hum Reprod Update. 2014;20(6):924–943. doi: 10.1093/humupd/dmu034. [DOI] [PubMed] [Google Scholar]
  • 149.Haneline LS. Redox Regulation of Stem and Progenitor Cells. Antioxidants & Redox Signaling. 2008;10(11):1849–1852. doi: 10.1089/ars.2008.2141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 150.Shiraki N, Shiraki Y, Tsuyama T, Obata F, Miura M, Nagae G, Aburatani H, Kume K, Endo F, Kume S. Methionine metabolism regulates maintenance and differentiation of human pluripotent stem cells. Cell Metab. 2014;19(5):780–794. doi: 10.1016/j.cmet.2014.03.017. [DOI] [PubMed] [Google Scholar]
  • 151.Wang J, Alexander P, Wu L, Hammer R, Cleaver O, McKnight SL. Dependence of mouse embryonic stem cells on threonine catabolism. Science. 2009;325(5939):435–439. doi: 10.1126/science.1173288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 152.Sperber H, Mathieu J, Wang Y, Ferreccio A, Hesson J, Xu Z, Fischer KA, Devi A, Detraux D, Gu H, Battle SL, Showalter M, Valensisi C, Bielas JH, Ericson NG, Margaretha L, Robitaille AM, Margineantu D, Fiehn O, Hockenbery D, Blau CA, Raftery D, Margolin AA, Hawkins RD, Moon RT, Ware CB, Ruohola-Baker H. The metabolome regulates the epigenetic landscape during naive-to-primed human embryonic stem cell transition. Nat Cell Biol. 2015;17(12):1523–1535. doi: 10.1038/ncb3264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 153.Vernardis SI, Terzoudis K, Panoskaltsis N, Mantalaris A. Human embryonic and induced pluripotent stem cells maintain phenotype but alter their metabolism after exposure to ROCK inhibitor. Sci Rep. 2017;7(1):42138. doi: 10.1038/srep42138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 154.Prigione A, Fauler B, Lurz R, Lehrach H, Adjaye J. The senescence-related mitochondrial/oxidative stress pathway is repressed in human induced pluripotent stem cells. Stem Cells. 2010;28(4):721–733. doi: 10.1002/stem.404. [DOI] [PubMed] [Google Scholar]
  • 155.Cho YM, Kwon S, Pak YK, Seol HW, Choi YM, Park DJ, Park KS, Lee HK. Dynamic changes in mitochondrial biogenesis and antioxidant enzymes during the spontaneous differentiation of human embryonic stem cells. Biochem Biophys Res Commun. 2006;348(4):1472–1478. doi: 10.1016/j.bbrc.2006.08.020. [DOI] [PubMed] [Google Scholar]
  • 156.Folmes CDL, Nelson TJ, Martinez-Fernandez A, Arrell DK, Lindor JZ, Dzeja PP, Ikeda Y, Perez-Terzic C, Terzic A. Somatic oxidative bioenergetics transitions into pluripotency-dependent glycolysis to facilitate nuclear reprogramming. Cell Metab. 2011;14(2):264–271. doi: 10.1016/j.cmet.2011.06.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 157.Panopoulos AD, Yanes O, Ruiz S, Kida YS, Diep D, Tautenhahn R, Herrerías A, Batchelder EM, Plongthongkum N, Lutz M, Berggren WT, Zhang K, Evans RM, Siuzdak G, Izpisua Belmonte JC. The metabolome of induced pluripotent stem cells reveals metabolic changes occurring in somatic cell reprogramming. Cell Res. 2012;22(1):168–177. doi: 10.1038/cr.2011.177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 158.Shyh-Chang N, Locasale JW, Lyssiotis CA, Zheng Y, Teo RY, Ratanasirintrawoot S, Zhang J, Onder T, Unternaehrer JJ, Zhu H, Asara JM, Daley GQ, Cantley LC. Influence of threonine metabolism on S-adenosylmethionine and histone methylation. Science. 2013;339(6116):222–226. doi: 10.1126/science.1226603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 159.Moussaieff A, Rouleau M, Kitsberg D, Cohen M, Levy G, Barasch D, Nemirovski A, Shen-Orr S, Laevsky I, Amit M, Bomze D, Elena-Herrmann B, Scherf T, Nissim-Rafinia M, Kempa S, Itskovitz-Eldor J, Meshorer E, Aberdam D, Nahmias Y. Glycolysis-mediated changes in acetyl-CoA and histone acetylation control the early differentiation of embryonic stem cells. Cell Metab. 2015;21(3):392–402. doi: 10.1016/j.cmet.2015.02.002. [DOI] [PubMed] [Google Scholar]
  • 160.Vazquez-Martin A, Cufi S, Corominas-Faja B, Oliveras-Ferraros C, Vellon L, Menendez JA. Mitochondrial fusion by pharmacological manipulation impedes somatic cell reprogramming to pluripotency: new insight into the role of mitophagy in cell stemness. Aging. 2012;4(6):393–401. doi: 10.18632/aging.100465. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 161.Huangfu D, Maehr R, Guo W, Eijkelenboom A, Snitow M, Chen AE, Melton DA. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol. 2008;26(7):795–797. doi: 10.1038/nbt1418. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 162.Shyh-Chang N, Daley GQ. Metabolic switches linked to pluripotency and embryonic stem cell differentiation. Cell Metab. 2015;21(3):349–350. doi: 10.1016/j.cmet.2015.02.011. [DOI] [PubMed] [Google Scholar]
  • 163.Johnson MT, Mahmood S, Patel MS. Intermediary metabolism and energetics during murine early embryogenesis. J Biol Chem. 2003;278(34):31457–31460. doi: 10.1074/jbc.R300002200. [DOI] [PubMed] [Google Scholar]
  • 164.Mandal S, Lindgren AG, Srivastava AS, Clark AT, Banerjee U. Mitochondrial function controls proliferation and early differentiation potential of embryonic stem cells. Stem Cells. 2011;29(3):486–495. doi: 10.1002/stem.590. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 165.Pereira SL, Grãos M, Rodrigues AS, Anjo SI, Carvalho RA, Oliveira PJ, Arenas E, Ramalho-Santos J. Inhibition of mitochondrial complex III blocks neuronal differentiation and maintains embryonic stem cell pluripotency. PLoS ONE. 2013;8(12):e82095. doi: 10.1371/journal.pone.0082095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 166.Yang Y, et al. Derivation of Pluripotent Stem Cells with In Vivo Embryonic and Extraembryonic Potency. Cell. 2017;169(2):243–257.e25. doi: 10.1016/j.cell.2017.02.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 167.Lancaster MA, Renner M, Martin C-A, Wenzel D, Bicknell LS, Hurles ME, Homfray T, Penninger JM, Jackson AP, Knoblich JA. Cerebral organoids model human brain development and microcephaly. Nature. 2013;501(7467):373–379. doi: 10.1038/nature12517. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 168.Camp JG, Badsha F, Florio M, Kanton S, Gerber T, Wilsch-Bräuninger M, Lewitus E, Sykes A, Hevers W, Lancaster M, Knoblich JA, Lachmann R, Pääbo S, Huttner WB, Treutlein B. Human cerebral organoids recapitulate gene expression programs of fetal neocortex development. Proc Natl Acad Sci USA. 2015;112(51):15672–15677. doi: 10.1073/pnas.1520760112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 169.Eiraku M, Sasai Y. Self-formation of layered neural structures in three-dimensional culture of ES cells. Curr Opin Neurobiol. 2012;22(5):768–777. doi: 10.1016/j.conb.2012.02.005. [DOI] [PubMed] [Google Scholar]
  • 170.Amin ND, Paşca SP. Building Models of Brain Disorders with Three-Dimensional Organoids. Neuron. 2018;100(2):389–405. doi: 10.1016/j.neuron.2018.10.007. [DOI] [PubMed] [Google Scholar]

Articles from Cell Stress are provided here courtesy of Shared Science Publishers

RESOURCES